190 related articles for article (PubMed ID: 19910068)
1. HPV-associated p16-expression and response to hypoxic modification of radiotherapy in head and neck cancer.
Lassen P; Eriksen JG; Hamilton-Dutoit S; Tramm T; Alsner J; Overgaard J;
Radiother Oncol; 2010 Jan; 94(1):30-5. PubMed ID: 19910068
[TBL] [Abstract][Full Text] [Related]
2. Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck.
Toustrup K; Sørensen BS; Lassen P; Wiuf C; Alsner J; Overgaard J;
Radiother Oncol; 2012 Jan; 102(1):122-9. PubMed ID: 21996521
[TBL] [Abstract][Full Text] [Related]
3. Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study.
Bentzen J; Toustrup K; Eriksen JG; Primdahl H; Andersen LJ; Overgaard J
Acta Oncol; 2015 Jul; 54(7):1001-7. PubMed ID: 25629651
[TBL] [Abstract][Full Text] [Related]
4. The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer: evaluation of the randomised DAHANCA 6&7 trial.
Lassen P; Eriksen JG; Krogdahl A; Therkildsen MH; Ulhøi BP; Overgaard M; Specht L; Andersen E; Johansen J; Andersen LJ; Grau C; Overgaard J;
Radiother Oncol; 2011 Jul; 100(1):49-55. PubMed ID: 21429609
[TBL] [Abstract][Full Text] [Related]
5. Radiosensitivity and effect of hypoxia in HPV positive head and neck cancer cells.
Sørensen BS; Busk M; Olthof N; Speel EJ; Horsman MR; Alsner J; Overgaard J
Radiother Oncol; 2013 Sep; 108(3):500-5. PubMed ID: 23953409
[TBL] [Abstract][Full Text] [Related]
6. Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial.
Overgaard J; Eriksen JG; Nordsmark M; Alsner J; Horsman MR;
Lancet Oncol; 2005 Oct; 6(10):757-64. PubMed ID: 16198981
[TBL] [Abstract][Full Text] [Related]
7. IAEA-HypoX. A randomized multicenter study of the hypoxic radiosensitizer nimorazole concomitant with accelerated radiotherapy in head and neck squamous cell carcinoma.
Hassan Metwally MA; Ali R; Kuddu M; Shouman T; Strojan P; Iqbal K; Prasad R; Grau C; Overgaard J
Radiother Oncol; 2015 Jul; 116(1):15-20. PubMed ID: 25913070
[TBL] [Abstract][Full Text] [Related]
8. Lack of prognostic and predictive value of CA IX in radiotherapy of squamous cell carcinoma of the head and neck with known modifiable hypoxia: an evaluation of the DAHANCA 5 study.
Eriksen JG; Overgaard J;
Radiother Oncol; 2007 Jun; 83(3):383-8. PubMed ID: 17543403
[TBL] [Abstract][Full Text] [Related]
9. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck.
Lassen P; Eriksen JG; Hamilton-Dutoit S; Tramm T; Alsner J; Overgaard J
J Clin Oncol; 2009 Apr; 27(12):1992-8. PubMed ID: 19289615
[TBL] [Abstract][Full Text] [Related]
10. HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).
Linge A; Lohaus F; Löck S; Nowak A; Gudziol V; Valentini C; von Neubeck C; Jütz M; Tinhofer I; Budach V; Sak A; Stuschke M; Balermpas P; Rödel C; Grosu AL; Abdollahi A; Debus J; Ganswindt U; Belka C; Pigorsch S; Combs SE; Mönnich D; Zips D; Buchholz F; Aust DE; Baretton GB; Thames HD; Dubrovska A; Alsner J; Overgaard J; Krause M; Baumann M;
Radiother Oncol; 2016 Dec; 121(3):364-373. PubMed ID: 27913065
[TBL] [Abstract][Full Text] [Related]
11. Impact of HPV-associated p16-expression on radiotherapy outcome in advanced oropharynx and non-oropharynx cancer.
Lassen P; Primdahl H; Johansen J; Kristensen CA; Andersen E; Andersen LJ; Evensen JF; Eriksen JG; Overgaard J;
Radiother Oncol; 2014 Dec; 113(3):310-6. PubMed ID: 25544647
[TBL] [Abstract][Full Text] [Related]
12. Does transfusion improve the outcome for HNSCC patients treated with radiotherapy? - results from the randomized DAHANCA 5 and 7 trials.
Hoff CM; Lassen P; Eriksen JG; Hansen HS; Specht L; Overgaard M; Grau C; Johansen J; Bentzen J; Andersen L; Evensen JF; Overgaard J
Acta Oncol; 2011 Oct; 50(7):1006-14. PubMed ID: 21790306
[TBL] [Abstract][Full Text] [Related]
13. Mature results from a Swedish comparison study of conventional versus accelerated radiotherapy in head and neck squamous cell carcinoma - The ARTSCAN trial.
Zackrisson B; Kjellén E; Söderström K; Brun E; Nyman J; Friesland S; Reizenstein J; Sjödin H; Ekberg L; Lödén B; Franzén L; Ask A; Wickart-Johansson G; Lewin F; Björk-Eriksson T; Lundin E; Dalianis T; Wennerberg J; Johansson KA; Nilsson P
Radiother Oncol; 2015 Oct; 117(1):99-105. PubMed ID: 26427805
[TBL] [Abstract][Full Text] [Related]
14. Tumor volume and cancer stem cell expression as prognostic markers for high-dose loco-regional failure in head and neck squamous cell carcinoma - A DAHANCA 19 study.
Kristensen MH; Sørensen MK; Tramm T; Alsner J; Sørensen BS; Maare C; Johansen J; Primdahl H; Bratland Å; Kristensen CA; Andersen M; Lilja-Fischer JK; Holm AIS; Samsøe E; Hansen CR; Zukauskaite R; Overgaard J; Eriksen JG
Radiother Oncol; 2024 Apr; 193():110149. PubMed ID: 38341096
[TBL] [Abstract][Full Text] [Related]
15. DAHANCA 10 - Effect of darbepoetin alfa and radiotherapy in the treatment of squamous cell carcinoma of the head and neck. A multicenter, open-label, randomized, phase 3 trial by the Danish head and neck cancer group.
Overgaard J; Hoff CM; Hansen HS; Specht L; Overgaard M; Lassen P; Andersen E; Johansen J; Andersen LJ; Evensen JF; Alsner J; Grau C
Radiother Oncol; 2018 Apr; 127(1):12-19. PubMed ID: 29523409
[TBL] [Abstract][Full Text] [Related]
16. Differential risk assessments from five hypoxia specific assays: The basis for biologically adapted individualized radiotherapy in advanced head and neck cancer patients.
Nordsmark M; Eriksen JG; Gebski V; Alsner J; Horsman MR; Overgaard J
Radiother Oncol; 2007 Jun; 83(3):389-97. PubMed ID: 17499868
[TBL] [Abstract][Full Text] [Related]
17. Randomized Phase 3 Trial of the Hypoxia Modifier Nimorazole Added to Radiation Therapy With Benefit Assessed in Hypoxic Head and Neck Cancers Determined Using a Gene Signature (NIMRAD).
Thomson DJ; Slevin NJ; Baines H; Betts G; Bolton S; Evans M; Garcez K; Irlam J; Lee L; Melillo N; Mistry H; More E; Nutting C; Price JM; Schipani S; Sen M; Yang H; West CM;
Int J Radiat Oncol Biol Phys; 2024 Jul; 119(3):771-782. PubMed ID: 38072326
[TBL] [Abstract][Full Text] [Related]
18. DAHANCA 28: A phase I/II feasibility study of hyperfractionated, accelerated radiotherapy with concomitant cisplatin and nimorazole (HART-CN) for patients with locally advanced, HPV/p16-negative squamous cell carcinoma of the oropharynx, hypopharynx, larynx and oral cavity.
Saksø M; Jensen K; Andersen M; Hansen CR; Eriksen JG; Overgaard J
Radiother Oncol; 2020 Jul; 148():65-72. PubMed ID: 32335364
[TBL] [Abstract][Full Text] [Related]
19. Treatment of head and neck cancer with CHART and nimorazole: phase II study.
Henk JM; Bishop K; Shepherd SF
Radiother Oncol; 2003 Jan; 66(1):65-70. PubMed ID: 12559522
[TBL] [Abstract][Full Text] [Related]
20. Prognostic biomarkers for the response to the radiosensitizer nimorazole combined with RCTx: a pre-clinical trial in HNSCC xenografts.
Koi L; Bitto V; Weise C; Möbius L; Linge A; Löck S; Yaromina A; Besso MJ; Valentini C; Pfeifer M; Overgaard J; Zips D; Kurth I; Krause M; Baumann M
J Transl Med; 2023 Aug; 21(1):576. PubMed ID: 37633930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
